遗忘
发表于 2025-3-23 10:46:35
http://reply.papertrans.cn/59/5891/589072/589072_11.png
Ambiguous
发表于 2025-3-23 17:21:21
http://reply.papertrans.cn/59/5891/589072/589072_12.png
Atrium
发表于 2025-3-23 20:34:31
http://reply.papertrans.cn/59/5891/589072/589072_13.png
keloid
发表于 2025-3-24 01:07:40
http://reply.papertrans.cn/59/5891/589072/589072_14.png
努力赶上
发表于 2025-3-24 03:05:53
Immune Therapy: What Can We Learn From Acquired Resistance?,sponse to these agents can be durable, but most patients will go on to develop resistance after initial tumor regression or prolonged disease stability. In patients with ‘acquired oligo-resistance,’ in whom progression is limited to two or less disease sites, local therapy may be an effective manage
无力更进
发表于 2025-3-24 10:16:21
Management of Brain Metastases, brain metastases is increasing. Lung cancer is the most frequent origin of metastases to the brain, and this diagnosis is associated with significant morbidity as well as decreased quality of life and a worse prognosis. The treatment for brain metastases in NSCLC has historically been local therapy
Type-1-Diabetes
发表于 2025-3-24 14:17:50
http://reply.papertrans.cn/59/5891/589072/589072_17.png
Neutral-Spine
发表于 2025-3-24 16:14:21
http://reply.papertrans.cn/59/5891/589072/589072_18.png
COM
发表于 2025-3-24 21:52:35
Small Cell Lung Cancer: Biology Advances,une checkpoint inhibitors have been approved for use in combination with etoposide plus a platinum agent as initial therapy for patients extensive stage SCLC; with the triplet regimen, the median overall survival is approximately 12 months. Over the past 4 years, several agents, including immune che
使混合
发表于 2025-3-24 23:51:13
http://reply.papertrans.cn/59/5891/589072/589072_20.png